Get the Stockscreener App
0.66
0.92%
0.006
After Hours:
.66
Passage Bio Inc stock is traded at $0.66, with a volume of 3.16M.
It is up +0.92% in the last 24 hours and up +28.48% over the past month.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease.
See More
Previous Close:
$0.654
Open:
$0.6488
24h Volume:
3.16M
Relative Volume:
5.47
Market Cap:
$40.77M
Revenue:
-
Net Income/Loss:
$-68.80M
P/E Ratio:
-0.322
EPS:
-2.05
Net Cash Flow:
$-59.06M
1W Performance:
-13.04%
1M Performance:
+28.48%
6M Performance:
-29.03%
1Y Performance:
-19.00%
1-Day Range:
$0.60
$0.72
1-Week Range:
$0.60
$0.7525
52-Week Range:
$0.451
$1.79
Passage Bio Inc Stock (PASG) Company Profile
Name
Passage Bio Inc
Sector
Industry
Phone
(267) 866-0312
Address
ONE COMMERCE SQUARE, PHILADELPHIA, PA
Compare PASG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PASG
Passage Bio Inc
|
0.66 | 40.77M | 0 | -68.80M | -59.06M | -1.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Passage Bio Inc Stock (PASG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-29-24 | Resumed | Wedbush | Outperform |
| Sep-03-24 | Initiated | Rodman & Renshaw | Buy |
| Mar-08-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-19-22 | Downgrade | Goldman | Buy → Neutral |
| Jul-01-21 | Initiated | Raymond James | Outperform |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Mar-04-21 | Upgrade | Goldman | Neutral → Buy |
| Feb-04-21 | Initiated | Guggenheim | Buy |
| Jan-25-21 | Initiated | Wedbush | Outperform |
| Jan-04-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-11-20 | Initiated | Citigroup | Neutral |
| Aug-14-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-25-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-25-20 | Initiated | Chardan Capital Markets | Buy |
| Mar-24-20 | Initiated | Cowen | Outperform |
| Mar-24-20 | Initiated | Goldman | Buy |
| Mar-24-20 | Initiated | JP Morgan | Overweight |
View All
Passage Bio Inc Stock (PASG) Latest News
Orbimed advisors sells $51,988 in Passage Bio shares By Investing.com - Investing.com South Africa
Orbimed advisors sells $51,988 in Passage Bio shares - Investing.com India
Orbimed Advisors LLC Reduces Stake in Passage Bio Inc - GuruFocus.com
WuXi Firms Surge on Slimmer Chances of US Biosecure Passage | Stock Market News - Mint
WuXi Firms Surge on Slimmer Chances of US Biosecure Passage - Yahoo Finance
ORBIMED ADVISORS LLC Reduces Holdings in Passage Bio Inc - GuruFocus.com
Orbimed advisors sells Passage Bio shares worth $77,338 By Investing.com - Investing.com Australia
Orbimed advisors sells Passage Bio shares worth $77,338 - Investing.com
Erste Asset Management GmbH Takes Position in Passage Bio, Inc. (NASDAQ:PASG) - MarketBeat
Yun Zhong, PhD, Joins Wedbush Securities as Senior Vice President, Equity Research, Biotechnology - Financial Times
Layoff Tracker: Agenus to Lay Off Staff as Part of Cost-Cutting Moves - BioSpace
Passage Bio assumed with an Outperform at Wedbush - Yahoo Finance
Gene and Cell Therapies Targeting CNS Disorders Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Revenue, Statistics, Therapies, Prevalence, Companies by DelveInsight - The Globe and Mail
Gene and Cell Therapies Targeting CNS Disorders Treatment - openPR
Passage Bio sees $284,519 in stock purchases by Lynx1 Capital - Investing.com South Africa
Insider Activity Roundup: Wednesday's Top Buys and Sells Revealed By Investing.com - Investing.com Canada
Insider Activity Roundup: Wednesday's Top Buys and Sells Revealed - Investing.com
Lynx1 Capital Management LP Increases Stake in Passage Bio Inc - GuruFocus.com
Passage Bio CEO Will Chou to Share Insights at Guggenheim Healthcare Innovation Conference! - MSN
Liquidia Corporation Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateOn November 13, 2024, Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company focusing on innovative therapies for rare cardiopulmonary dise - Defense World
Horizon Space Acquisition I Corp. Approved for Listing on Nasdaq Capital Market - Defense World
Seres Therapeutics Receives Notification from Nasdaq Regarding Bid Price Requirement - Defense World
BioRestorative Therapies Provides Business Update and Financial Results for Q3 2024 - Defense World
Metal Sky Star Acquisition Amends Investment Management Trust Agreement and Extends Business Combination Period - Defense World
Nikola Corporation Enters Material Definitive Agreements, Modifies Convertible Notes – 8-K Filing Highlights - Defense World
Air Industries Group to Release Financial Results for Q3 2024 - Defense World
AgriFORCE Growing Systems Announces Strategic Shift Towards Sustainable Technology Initiatives - Defense World
Cognition Therapeutics Reports Financial Results for the Third Quarter 2024UNAUDITED – On November 13, 2024, Cognition Therapeutics, Inc. (NASDAQ: CGTX) disclosed its financial results for the third quarter ending September 30, 2024. Within the detai - Defense World
Orange County Bancorp, Inc. (NASDAQ: OBT) Distributes Investor Presentation and Financial Disclosure - Defense World
Digital Brands Group (NASDAQ: DBGI) Announces Strategic Partnership with VaynerCommerce - Defense World
MRC Global Inc. Enters into Fifth Amended and Restated Loan Agreement - Defense World
Intevac (NASDAQ: IVAC) Enters into Letter Agreement with Palogic Value Management, L.P.Santa Clara, CA, November 13, 2024 – Intevac, Inc. (NASDAQ: IVAC) disclosed today in a Form 8-K filing that on November 8, 2024, the company entered into a letter - Defense World
Advance Auto Parts Enters Amendment to Credit Agreement - Defense World
Sound Point Meridian Capital, Inc. (NYSE: SPMC) Announces Financial Results for Quarter Ended September 30, 2024 - Defense World
Tetra Tech Reports Record Fiscal 2024 and Fourth Quarter ResultsOn November 13, 2024, Tetra Tech, Inc. (NASDAQ: TTEK) released its financial results for the fourth fiscal quarter and the fiscal year ended September 29, 2024. According to the report - Defense World
Roth CH Acquisition II Files 8-K Report with SEC Detailing Company Updates and Investor Presentation - Defense World
Capricor Therapeutics Announces Financial Results for Third Quarter 2024 and Strategic DevelopmentsSAN DIEGO, November 13, 2024 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR) recently disclosed its financial outcomes for the third - Defense World
Predictive Oncology Inc. Issues Press Release Detailing Financial Results for Q3 2024Predictive Oncology Inc., a leading biopharmaceutical company, released a pivotal press release detailing its financial results for the quarter ending September 30 - Defense World
Flutter Entertainment Announces Launch of Share Repurchase Program - Defense World
374Water Inc. Reports Third Quarter 2024 Results and Business Update - Defense World
Broadwind, Inc. Reports Financial Results for Quarter Ending September 30, 2024 - Defense World
Workhorse Group Reschedules Earnings Call to November 19, 2024 - Defense World
Cabaletta Bio Reports Q3 2024 Financial Results and Clinical Trial Advancements - MyChesCo
Passage Bio stock hits 52-week low at $0.54 amid market challenges - Investing.com India
Passage Bio Advances PBFT02 Gene Therapy Program Amidst Positive Q3 2024 Results - MSN
Vestal Point Capital, LP Increases Stake in Passage Bio Inc - GuruFocus.com
Passage Bio Achieves Milestones in Gene Therapy Trials - Yahoo Finance
Passage Bio Shows Progress in Gene Therapy Trials - TipRanks
PASGPassage Bio, Inc. Latest Stock News & Market Updates - StockTitan
Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights - GlobeNewswire
Passage Bio's Q3 Shows Progress: Clinical Trial Advances, Cash Runway Extended to 2026 | PASG Stock News - StockTitan
Passage Bio Inc Stock (PASG) Financials Data
Revenue
Net Income
Cash Flow
EPS
Passage Bio Inc Stock (PASG) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 10% Owner |
Dec 10 '24 |
Sale |
0.80 |
8,015 |
6,412 |
7,635,270 |
| ORBIMED ADVISORS LLC | 10% Owner |
Dec 11 '24 |
Sale |
0.80 |
80 |
64 |
7,635,190 |
| ORBIMED ADVISORS LLC | 10% Owner |
Dec 04 '24 |
Sale |
0.79 |
76,200 |
60,198 |
7,718,369 |
| ORBIMED ADVISORS LLC | 10% Owner |
Dec 06 '24 |
Sale |
0.82 |
20,903 |
17,140 |
7,697,466 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):